Cheetah Medical reveals promising study results for noninvasive blood monitoring tech

Cheetah Nicom noninvasive blood monitoring system--Courtesy of Cheetah Medical

Noninvasive hemodynamic monitoring company Cheetah Medical is touting results from a new study showing that using the company's technology to assess fluid responsiveness could save hospitals time and money.

The Newton, MA-based company unveiled results at a recent American Society of Anesthesiologists (ASA) annual meeting from a study conducted by Duke University physicians which shows that hospitals can avoid $3 of costs for every $1 they spend during surgery by using the Cheetah Nicom noninvasive hemodynamic monitoring system. Hospitals typically administer IV fluids as a first step to resuscitate patients with severe infections, life-threatening trauma or those undergoing major surgery who experience cardiac function. But too much fluid can cause serious complications, increase the length of hospital and ICU stays and in some cases, increase the risk of death.

Physicians found that traditional methods are often not sensitive or specific enough to identify hemodynamic deterioration quickly, and that resuscitating critically ill patients with fluids requires continuous monitoring, Cheetah said in a statement. A noninvasive hemodynamic monitoring system could eventually lead to a decreased hospital stay and lower rates of death after surgery.

"The FDA-cleared and CE-marked Cheetah Nicom system is totally noninvasive and … is designed to be the very best technology for continuous fluid assessment in the operating room or a critical care setting," Chris Hutchison, president and CEO of Cheetah Medical, said in a statement.

The promising study data deals more cards in Cheetah's favor, as the company attempts to make headway with its real-time, non-invasive cardiac output monitoring system. Last year, Cheetah raised $13.77 million in financing during the first quarter, drawing support from investors such as Ascension Health Ventures, Fletcher Spaght Ventures, MVM Life Science Partners, Robert Bosch Venture Capital GmbH and an undisclosed investor. In June, the company picked up an additional $5 million from HighCap Partners to help propel domestic and overseas sales efforts for its blood flow diagnostic technology.

Cheetah is not the only company developing noninvasive blood monitoring technology. Covidien ($COV) bills its Nellcor blood oxygenation monitor as reducing clinically insignificant alerts by 60%, leading to more reliable readings and providing an early warning of dangerous medical conditions. In 2013, smartphone maker BlackBerry launched a $97 million fund to support entrepreneurs developing noninvasive medical diagnostic technology. The company's Quantum Valley Investments fund was designed to focus on as many as two dozen companies, including a startup creating a scanner with quantum sensors to scan with body for vital diagnostics.

- read the release

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.